Mnemosyne Pharmaceuticals Adds Additional $6M to Series A
July 08, 2013
Rhode Island-based Mnemosyne Pharmaceuticals, a neuroscience-focused biotech, has increased its Series A financing with an additional $6 million expansion round from new investor Atlas Venture and previous backer Clal Biotechnology Industries, bringing the total Series A financing to $11.4 million. The round also included participation from Slater Technology Fund. Proceeds from the financing will support the company’s drug discovery efforts and will focus on Mnemosyne’s two lead programs in schizophrenia and Rett Syndrome.